阿斯利康公司的COVID-19候选疫苗在美国开始三期临床测试(美國美中報道)

阿斯利康(AstraZeneca)公司的COVID-19候选疫苗在美国开始三期临床测试

对研究性疫苗AZD1222能否预防COVID-19的一项三期临床试验已经开始了。该试验将在美国的80个地点招募三万名志愿者,包括通过美国国家过敏症和传染病研究所(NIAID)的COVID-19预防网络。

AZD1222由牛津大学詹纳研究所(Jenner Institute)和牛津疫苗小组研发。阿斯利康公司获得授权对该候选疫苗进行进一步研发。这种疫苗利用一种病毒载体传递SARS-CoV-2病毒的一种刺突蛋白,从而引发免疫反应。SARS-CoV-2是导致COVID-19的病毒。

这项试验获得“曲速行动”的支持以及“加速COVID-19治疗干预和疫苗”(ACTIV)合作伙伴关系项目的指导。该项目整合多项研究性疫苗的数据,来评估每种候选疫苗的相对有效性。

了解更多信息:https://www.nih.gov/news-events/news-releases/phase-3-clinical-testing-us-astrazeneca-covid-19-vaccine-candidate-begins

Phase 3 Clinical Testing in the U.S. of AstraZeneca COVID-19 Vaccine Candidate Begins

A Phase 3 clinical trial of investigational vaccine AZD1222 to prevent COVID19 has begun. The trial will enroll 30k volunteers at 80 sites in the US, including NIAID COVID-19 Prevention Network.

Oxford University’s Jenner Institute and Oxford Vaccine Group developed AZD1222. The candidate vaccine was licensed to AstraZeneca for further development. The vaccine uses a viral vector to deliver a SARS-CoV-2 spike protein to induce an immune response. SARS-CoV-2 is the virus that causes #COVID19.

This trial is supported by Operation #WarpSpeed & guided by the #ACTIV partnership which harmonizes data for multiple investigational vaccines to assess the relative effectiveness of each candidate.

More info: https://www.nih.gov/news-events/news-releases/phase-3-clinical-testing-us-astrazeneca-covid-19-vaccine-candidate-begins(来源:美国驻华大使馆)

分享: